FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月13日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年9月30日 | 1,067,049,081 | | 3,579,100 | | 1,070,628,181 | | 1) ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 醫渡科技有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 ...

Core Points - Yidu Tech (02158) shares rose over 6%, currently up 6.27% at HKD 7.12, with a trading volume of HKD 112 million [1] - The company announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - At the "First Medical Artificial Intelligence Conference and Health Industry AI Application and Development Exhibition" held in Jinan, Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, introduced the "Doctor Copilot" built on the foundation of "big data + Yidu domain-specific large model," which has been implemented in several hospitals to enhance diagnostic efficiency and quality, aiding in the intelligent and standardized upgrade of clinical practices [1] Summary by Categories Financial Performance - Yidu Tech's stock price increased by 6.27%, reaching HKD 7.12, with a trading volume of HKD 112 million [1] Project Development - The company secured a project worth approximately RMB 55.82 million for the Phase III clinical research of SMR001 eye drops [1] Technological Innovation - The "Doctor Copilot" technology, which integrates clinical workflows, has been successfully implemented in multiple hospitals, improving diagnostic efficiency and quality [1]

消息面上，医渡科技公布，近期，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限 公司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。此 外，由《中国卫生信息管理杂志》社主办的"首届医学人工智能大会暨卫生健康行业AI应用与产业发展 展览会"近日于济南举办。在大会"AI驱动医疗质量提升"论坛上，医渡科技技术创新副总裁、AI架构师 李林峰博士介绍，医渡科技以"大数据+医渡垂域大模型"为技术底座，构建了深度融合临床工作流的"医 生Copilot"。目前，医生Copilot已在多家医院落地应用，有效提升诊疗效率与质量，助力临床实现智能 化、规范化升级。 智通财经APP获悉，医渡科技(02158)涨超6%，截至发稿，涨6.27%，报7.12港元，成交额1.12亿港元。 ...

Core Viewpoint - The stock of Yidu Tech (02158) has seen a significant increase, rising over 14% in late trading, with a current price of HKD 6.57 and a trading volume of HKD 466 million [1] Group 1: Company Developments - Yidu Tech's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] - On September 16, during the 2025 Tencent Digital Ecosystem Conference's medical session, Yidu Tech's Senior Solutions Expert Shi Chengfa delivered a speech titled "AI Empowering the Full Process of Clinical Trials," discussing how AI can enhance the efficiency and quality of clinical trials, thereby promoting high-quality development in the industry [1]

Group 1 - The core point of the article is that Yidu Technology (02158) experienced a significant stock price increase, rising over 14% in late trading, with a current price of HKD 6.57 and a trading volume of HKD 466 million [1] - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] - On September 16, during the 2025 Tencent Digital Ecosystem Conference's medical session, Yidu Technology's Senior Solutions Expert Shi Chengfa delivered a speech on "AI Empowering the Full Process of Clinical Trials," discussing how AI can enhance the efficiency and quality of clinical trials, thereby promoting high-quality development in the industry [1]

医渡科技(02158)发布公告，于2025年9月29日斥资192.71万港元回购33.5万股股份。 ...

格隆汇9月29日丨医渡科技(02158.HK)公告，9月29日耗资192.7万港元回购33.5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年9月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

格隆汇9月26日丨医渡科技(02158.HK)公告，9月26日耗资200万港元回购35.3万股。 ...